Susquehanna International Group
MDGL icon

Susquehanna International Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Susquehanna International Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8M Sell
55,100
-58,300
-51% -$27.9M ﹤0.01% 1778
2025
Q4 		$66M Sell
113,400
-6,400
-5% -$3.27M 0.01% 1156
2025
Q3 		$54.9M Sell
119,800
-900
-0.7% -$336K 0.01% 1275
2025
Q2 		$36.5M Buy
120,700
+26,500
+28% +$7.9M 0.01% 1417
2025
Q1 		$31.2M Sell
94,200
-118,000
-56% -$38.8M 0.01% 1354
2024
Q4 		$65.5M Buy
212,200
+41,700
+24% +$11.7M 0.01% 941
2024
Q3 		$36.2M Buy
170,500
+16,700
+11% +$4.27M 0.01% 1327
2024
Q2 		$43.1M Sell
153,800
-180,000
-54% -$42.8M 0.01% 1086
2024
Q1 		$89.1M Buy
333,800
+236,000
+241% +$55.6M 0.02% 732
2023
Q4 		$22.6M Sell
97,800
-6,500
-6% -$1.14M ﹤0.01% 1674
2023
Q3 		$15.2M Sell
104,300
-62,400
-37% -$11.7M ﹤0.01% 2058
2023
Q2 		$38.5M Buy
166,700
+64,700
+63% +$17.5M 0.01% 1174
2023
Q1 		$24.7M Sell
102,000
-300,800
-75% -$82M 0.01% 1493
2022
Q4 		$117M Buy
402,800
+377,800
+1,511% +$36.9M 0.03% 492
2022
Q3 		$1.63M Buy
25,000
+6,500
+35% +$452K ﹤0.01% 5401
2022
Q2 		$1.32M Sell
18,500
-16,000
-46% -$1.18M ﹤0.01% 5847
2022
Q1 		$3.38M Buy
34,500
+14,100
+69% +$1.19M ﹤0.01% 4395
2021
Q4 		$1.73M Buy
20,400
+3,400
+20% +$279K ﹤0.01% 5858
2021
Q3 		$1.36M Buy
17,000
+7,600
+81% +$656K ﹤0.01% 6754
2021
Q2 		$916K Buy
9,400
+6,200
+194% +$734K ﹤0.01% 8012
2021
Q1 		$374K Sell
3,200
-800
-20% -$93.3K ﹤0.01% 10133
2020
Q4 		$445K Sell
4,000
-44,900
-92% -$5.49M ﹤0.01% 8531
2020
Q3 		$5.81M Sell
48,900
-29,000
-37% -$3.15M ﹤0.01% 2868
2020
Q2 		$8.82M Sell
77,900
-20,700
-21% -$2.04M ﹤0.01% 2280
2020
Q1 		$6.58M Sell
98,600
-23,700
-19% -$1.97M ﹤0.01% 2223
2019
Q4 		$11.1M Buy
122,300
+79,600
+186% +$7.72M ﹤0.01% 1977
2019
Q3 		$3.68M Sell
42,700
-15,400
-27% -$1.44M ﹤0.01% 3171
2019
Q2 		$6.09M Sell
58,100
-28,900
-33% -$3.1M ﹤0.01% 2456
2019
Q1 		$10.9M Buy
87,000
+55,100
+173% +$6.85M ﹤0.01% 1661
2018
Q4 		$3.6M Sell
31,900
-32,700
-51% -$5.06M ﹤0.01% 2683
2018
Q3 		$13.8M Buy
64,600
+37,700
+140% +$9.46M ﹤0.01% 1635
2018
Q2 		$7.52M Buy
+26,900
New +$4.72M ﹤0.01% 2244
2016
Q1 		– Sell
-4,331
Closed -$53K – 9409
2015
Q4 		$53K Sell
4,331
-726
-14% -$19.9K ﹤0.01% 9092
2015
Q3 		$308K Sell
5,057
-1,509
-23% -$109K ﹤0.01% 7999
2015
Q2 		$512K Sell
6,566
-345
-5% -$29K ﹤0.01% 7599
2015
Q1 		$469K Sell
6,911
-3,918
-36% -$336K ﹤0.01% 7218
2014
Q4 		$1M Sell
10,829
-4,400
-29% -$455K ﹤0.01% 5879
2014
Q3 		$1.6M Sell
15,229
-4,608
-23% -$641K ﹤0.01% 5018
2014
Q2 		$2.84M Buy
19,837
+3,774
+23% +$552K ﹤0.01% 4006
2014
Q1 		$2.42M Buy
16,063
+792
+5% +$156K ﹤0.01% 4014
2013
Q4 		$2.8M Buy
15,271
+6,357
+71% +$1.16M ﹤0.01% 3750
2013
Q3 		$1.97M Buy
8,914
+4,025
+82% +$856K ﹤0.01% 4126
2013
Q2 		$854K Buy
+4,889
New +$1.27M ﹤0.01% 5259

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's MDGL Position: Q1 2026 in Review

Susquehanna International Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 66% in Q1 2026, selling an estimated $20.2M and leaving 22,216 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2887.

Susquehanna International Group first reported a position in MDGL in Q2 2013 and has held it in 42 quarters since. The position peaked at $48.1M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Susquehanna International Group held 22,216 shares of Madrigal Pharmaceuticals worth $11.6M as of Q1 2026.
  • Susquehanna International Group sold 42,250 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $20.2M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2887 holding.
  • Susquehanna International Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's Madrigal Pharmaceuticals position peaked at $48.1M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.